{"ticker": {"uuid": "8d1d1791-96e4-4ced-8f03-56f9a1cd0289", "symbol": "SNDX", "name": "Syndax Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Syndax Pharmaceuticals (NASDAQ:SNDX) Earns \"Buy\" Rating from HC Wainwright", "summary": "HC Wainwright has reiterated a \"buy\" rating on Syndax Pharmaceuticals (NASDAQ:SNDX), setting a $40 price target which suggests a 65.8% upside. The company reported better-than-expected quarterly EPS of ($0.48) and a significant year-over-year revenue increase of 224.3%, although ", "url": "https://www.marketbeat.com/instant-alerts/syndax-pharmaceuticals-nasdaqsndx-earns-buy-rating-from-hc-wainwright-2026-07-15/", "source_name": "MarketBeat", "published_at": "2026-07-15T12:46:50", "published_display": "15 Jul 2026 12:46", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Syndax Pharmaceuticals stock rating at buy", "summary": "H.C. Wainwright reiterated a Buy rating and a $40.00 price target for Syndax Pharmaceuticals (NASDAQ:SNDX) after the company's research and development day. The analyst firm highlighted two new assets, SNDX-62122 and SNDX-4321, with SNDX-62122 showing promise as a next-generation", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-syndax-pharmaceuticals-stock-rating-at-buy-93CH-4793279", "source_name": "Investing.com", "published_at": "2026-07-15T12:46:49", "published_display": "15 Jul 2026 12:46", "sentiment": "positive", "sentiment_pct": 81, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SNDX6417984 Bond Coupon Profile \u2014 Rate & Payments", "summary": "This article provides a bond coupon profile for Syndax Pharmaceuticals, Inc. (SNDX6417984). It indicates a current coupon rate of 2.25% with the next interest payment scheduled for December 15, 2026. The profile offers an overview of the bond's interest payments and redemption de", "url": "https://www.tradingview.com/symbols/FINRA-SNDX6417984/profile-coupon/", "source_name": "TradingView", "published_at": "2026-07-15T03:46:49", "published_display": "15 Jul 2026 03:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals Inc to Host R&D Day Transcript", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1tRXZvUFVnWG9QYVZzQzROcTYtWmJUWGFHd1piNkpiVVZ1SzE5ZC0xN0pvYzFCdzNmbVdsb2RYVWFaZ3Y2dkZSVFNSTzRqdDZnSE41R1hfeFVEdTRDRFluZHhlaGNsNmM?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-14T22:02:30+00:00", "published_display": "14 Jul 2026 22:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Fresh Look At Syndax Pharmaceuticals (NASDAQ:SNDX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxQdWdrWk1vMVc2QkNpTlctYU5iSkIwOG9qa0tmRmxiS29Cblp6cWl6UlduYTZvWUJGUzdyUjI0RGVjR0RNNnRKbV96cDFUd29yNFhfc21ZRnI5WTE1UzRSYWFfX1F3M2pSd3Z3cVpha0RueE11ODBPVzFLYWt5SlNkOG5lOGxfZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T20:48:00+00:00", "published_display": "14 Jul 2026 20:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SNDX6417984 Bond Profile \u2014 Key Metrics", "summary": "This article provides key metrics for the Syndax Pharmaceuticals, Inc. 2.25% 15-JUN-2031 bond, identified as SNDX6417984 FINRA. It details the bond's issuer, issue date, maturity date, outstanding amount, face value, minimum denomination, and coupon rate. Additionally, it gives a", "url": "https://www.tradingview.com/symbols/FINRA-SNDX6417984/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-14T21:14:05", "published_display": "14 Jul 2026 21:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push", "summary": "Syndax Pharmaceuticals is expanding its pipeline beyond its approved drugs Revuforj and Niktimvo, focusing on new indications in myelofibrosis and EGFR-mutated non-small cell lung cancer. The company plans a proof-of-principle trial for Revuforj in myelofibrosis and is advancing ", "url": "https://finance.yahoo.com/healthcare/articles/syndax-pharmaceuticals-maps-growth-beyond-200221267.html", "source_name": "Market source", "published_at": "2026-07-14T20:14:05", "published_display": "14 Jul 2026 20:14", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies - Slideshow (NASDAQ:SNDX)", "summary": "Syndax Pharmaceuticals, Inc. (SNDX) has published a slide deck discussing its pipeline expansion and the next phase of innovation for its lead therapies. This information was shared in conjunction with an event, indicating a focus on future development and strategic direction for", "url": "https://seekingalpha.com/article/4922013-syndax-pharmaceuticals-inc-sndx-discusses-pipeline-expansion-and-next-phase-of-innovation-for", "source_name": "Seeking Alpha", "published_at": "2026-07-14T16:40:27", "published_display": "14 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet", "summary": "Wall Street analysts project Syndax Pharmaceuticals (SNDX) could see a 70.38% surge, with a mean price target of $39. While price targets alone can be misleading, strong agreement among analysts on higher earnings estimates and a Zacks Rank #2 (Buy) suggest a potential upside. In", "url": "https://ca.finance.yahoo.com/news/wall-street-analysts-think-syndax-135502317.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-14T13:40:27", "published_display": "14 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SNDX: New pipeline assets and late-stage programs drive clinical and commercial growth through 2027", "summary": "Syndax Pharmaceuticals (SNDX) is expanding its pipeline with new EGFR and menin inhibitors and advancing late-stage programs in leukemia, GVHD, and IPF. The company anticipates multiple clinical milestones through 2027, supported by strategic partnerships and a strong financial s", "url": "https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3694655:0-sndx-new-pipeline-assets-and-late-stage-programs-drive-clinical-and-commercial-growth-through-2027/", "source_name": "TradingView", "published_at": "2026-07-14T12:40:27", "published_display": "14 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax (NASDAQ: SNDX) details pipeline expansion and 2026-27 clinical catalysts", "summary": "Syndax Pharmaceuticals (NASDAQ: SNDX) has outlined its expanded pipeline and clinical development plans for 2026-2027, including new assets SNDX-4321 for EGFR-mutated NSCLC and SNDX-62122 for myelofibrosis. The company also highlighted the commercial success of its FDA-approved d", "url": "https://www.stocktitan.net/sec-filings/SNDX/8-k-syndax-pharmaceuticals-inc-reports-material-event-dfbb39fcc295.html", "source_name": "Stock Titan", "published_at": "2026-07-14T12:40:27", "published_display": "14 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event", "summary": "Syndax Pharmaceuticals is hosting an R&D Event to showcase its late-stage programs and introduce new pipeline assets, SNDX-4321 for NSCLC and SNDX-62122 for MF. The company aims to expand its leadership in menin and CSF-1R inhibition, building on recent successes with Revuforj an", "url": "https://www.globenewswire.com/de/news-release/2026/07/14/3326768/0/en/Syndax-to-Highlight-Late-Stage-Programs-and-Unveil-New-Pipeline-Assets-at-R-D-Event.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T11:40:27", "published_display": "14 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Adds Two Pipeline Assets for Lung Cancer and Myelofibrosis", "summary": "Syndax Pharmaceuticals announced two new pipeline assets, SNDX-4321 for EGFR-mutated non-small cell lung cancer (NSCLC) and SNDX-62122 for myelofibrosis (MF), during its R&D event. SNDX-4321, a novel EGFR inhibitor, is expected to have an IND submission by year-end 2026 and a Pha", "url": "https://www.stocktitan.net/news/SNDX/syndax-to-highlight-late-stage-programs-and-unveil-new-pipeline-6e0syve6xmz8.html", "source_name": "Stock Titan", "published_at": "2026-07-14T11:40:27", "published_display": "14 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Technical Reactions to SNDX Trends in Macro Strategies", "summary": "This article provides a technical analysis of Syndax Pharmaceuticals Inc. (NASDAQ: SNDX), highlighting strong sentiment across all time horizons and an exceptional 52.6:1 risk-reward setup. It outlines three institutional trading strategies (Position, Momentum Breakout, and Risk ", "url": "https://news.stocktradersdaily.com/news_release/20/Technical_Reactions_to_SNDX_Trends_in_Macro_Strategies_071026014202_1783662122.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-10T01:42:00", "published_display": "10 Jul 2026 01:42", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Syndax Pharmaceuticals For: 9 July By Investing.com", "summary": "This article from Investing.com announces a Form 4 filing for Syndax Pharmaceuticals, dated July 9th. The filing pertains to stock market activity for the company, whose stock symbol is SNDX. The brief entry reiterates the date and company information.", "url": "https://ng.investing.com/news/stock-market-news/form-4-syndax-pharmaceuticals-for-9-july-93CH-2593975", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T22:09:18", "published_display": "09 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells 32,375 Shares", "summary": "Syndax Pharmaceuticals CEO Michael Metzger sold 32,375 shares of SNDX stock on July 8th for approximately $784,770, reducing his stake by 6.26%. Despite the insider sale, the stock rose 1.1% to $24.84, nearing its 52-week high, and analysts maintain a \"Moderate Buy\" consensus wit", "url": "https://www.marketbeat.com/instant-alerts/syndax-pharmaceuticals-nasdaqsndx-ceo-sells-32375-shares-2026-07-09/", "source_name": "MarketBeat", "published_at": "2026-07-09T21:41:14", "published_display": "09 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax (SNDX) CEO Metzger exercises options and sells 32,375 shares under 10b5-1 plan", "summary": "Syndax Pharmaceuticals CEO Michael A. Metzger exercised stock options for 32,375 shares at $6.38 each and subsequently sold all 32,375 shares on the open market at an average price of $24.2402 per share. These transactions were executed under a pre-established Rule 10b5-1 trading", "url": "https://www.stocktitan.net/sec-filings/SNDX/form-4-syndax-pharmaceuticals-inc-insider-trading-activity-8881b521c490.html", "source_name": "Stock Titan", "published_at": "2026-07-09T21:41:14", "published_display": "09 Jul 2026 21:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals Insider Sold Shares Worth $784,776, According to a Recent SEC Filing", "summary": "An insider at Syndax Pharmaceuticals recently sold shares worth $784,776, as detailed in a recent SEC filing. The sale involved 31,500 shares at an average price of $24.91 per share. This transaction increases transparency regarding insider activity at the company.", "url": "https://www.moomoo.com/news/post/72735768/syndax-pharmaceuticals-insider-sold-shares-worth-784776-according-to-a?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-09T21:09:18", "published_display": "09 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Syndax Pharmaceuticals For: 8 July By Investing.com", "summary": "This article from Investing.com reports on a Form 144 filing for Syndax Pharmaceuticals (SNDX) for July 8, 2026. The brief piece indicates that shares of Syndax Pharmaceuticals were up 5.68% at the time of publication, suggesting market interest stemming from the filing.", "url": "https://ca.investing.com/news/stock-market-news/form-144-syndax-pharmaceuticals-for-8-july-93CH-4726031", "source_name": "Investing.com Canada", "published_at": "2026-07-08T21:10:17", "published_display": "08 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SNDX insider files to sell 32,375 shares (NASDAQ: SNDX)", "summary": "A Form 144 filing indicates a proposed sale of 32,375 shares of Syndax Pharmaceuticals Inc (NASDAQ: SNDX) common stock on July 8, 2026, through the exercise of stock options. The filing also disclosed a previous sale of 6,847 shares on June 1, 2026, for $130,024.53. The transacti", "url": "https://www.stocktitan.net/sec-filings/SNDX/144-syndax-pharmaceuticals-inc-sec-filing-6ba5df804cdd.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:10:17", "published_display": "08 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Syndax Pharmaceuticals (SNDX) Is Up 6.3% After Broad Russell Value Index Removal And What's Next", "summary": "Syndax Pharmaceuticals (SNDX) experienced a 6.3% increase in stock value despite being removed from several Russell value indexes on June 27, 2026. This removal primarily impacts the stock's ownership structure and trading patterns due to benchmark-driven portfolio rebalancing, r", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/why-syndax-pharmaceuticals-sndx-is-up-63-after-broad-russell", "source_name": "Simply Wall Street", "published_at": "2026-07-08T09:10:48", "published_display": "08 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals holds steady as investors await a fresh catalyst", "summary": "Syndax Pharmaceuticals (SNDX) stock is holding steady with no immediate new market-moving filings, shifting focus to its US-listed setup and pipeline. The company, a US biotech firm specializing in oncology and hematology, relies heavily on clinical data, regulatory milestones, a", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/syndax-pharmaceuticals-holds-steady-as-investors-await-a-fresh-catalyst/69714064", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T12:40:11", "published_display": "07 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SG Americas Securities LLC Has $900,000 Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX", "summary": "SG Americas Securities LLC reduced its stake in Syndax Pharmaceuticals by 70.2% in Q1, now holding 38,548 shares worth $900,000. Despite this, the company has an average \"Moderate Buy\" rating, although some analysts like Weiss Ratings maintain a \"sell.\" Recent insider selling by ", "url": "https://www.marketbeat.com/instant-alerts/filing-sg-americas-securities-llc-has-900000-stock-holdings-in-syndax-pharmaceuticals-inc-sndx-2026-07-06/", "source_name": "MarketBeat", "published_at": "2026-07-06T09:11:07", "published_display": "06 Jul 2026 09:11", "sentiment": "negative", "sentiment_pct": 37, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals (SNDX) Reports Strong Revuforj Data, Is The Upside Already Priced In?", "summary": "Syndax Pharmaceuticals (SNDX) recently released encouraging Phase 1/2 data for its Revuforj combination regimen in acute myeloid leukemia, showing high response rates and attracting investor interest. Despite a significant one-year share price return, the stock is trading below a", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-sndx-reports-strong-revuforj-data-is", "source_name": "Simply Wall Street", "published_at": "2026-07-04T20:40:46", "published_display": "04 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)", "summary": "Syndax Pharmaceuticals announced inducement grants to eight new employees for up to 250,700 shares of common stock under its 2023 Inducement Plan. These stock options will vest over four years, with a portion vesting on the one-year anniversary and the remainder monthly thereafte", "url": "https://www.globenewswire.com/news-release/2026/07/01/3320972/0/en/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-07-02T07:09:46", "published_display": "02 Jul 2026 07:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax awards stock options to 8 new hires in July", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQeXVtM2lqcXNmZC10aXdDLU5SQ3M3WFZQa3VXZDZld18yZmlYc0VJVzVVR0tEQ0dmd1hFQVgtT1JrUW1mM2E5Yi1LZ3R0NTNqUXZDS25OUEhyMTl4UjVQNDRzQzRqWXRGLVFaYzNrblNjSHkzM2h6MVc0elVhY3RKSjFBci1ZM0d6QTNSWFd4b2xMMm8wYS1XQ1NyVm9UaGdKalRrYlR2WDZGUTY4TFcwT1RRZzNhS0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of \"Moderate Buy\" by Analysts", "summary": "Syndax Pharmaceuticals (NASDAQ:SNDX) has received a \"Moderate Buy\" consensus rating from analysts, with an average 12-month price target of $42.55. Recent analyst updates include price target increases from JPMorgan, Barclays, and Goldman Sachs, though Wall Street Zen downgraded ", "url": "https://www.marketbeat.com/instant-alerts/syndax-pharmaceuticals-inc-nasdaqsndx-given-consensus-rating-of-moderate-buy-by-analysts-2026-07-01/", "source_name": "MarketBeat", "published_at": "2026-07-01T06:09:30", "published_display": "01 Jul 2026 06:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Purchase/sale of business (net) of Syndax Pharmaceuticals Inc \u2013 SWB:1T3", "summary": "This article provides financial information for Syndax Pharmaceuticals Inc, listed on the Stuttgart Stock Exchange under the ticker SWB:1T3. It specifically highlights the \"Purchase/sale of business (net)\" data, indicating that currently, there are no recorded values for this met", "url": "https://www.tradingview.com/symbols/SWB-1T3/financials-cash-flow/purchase-sale-business/", "source_name": "TradingView", "published_at": "2026-06-30T08:40:20", "published_display": "30 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPNWtMam05Z1JYQ0ptZzZOUXVtVlVOQXFOSnZKZ19mQ212VVlqX213UndyVnU0OVhQeVpRRGNsWHlDMGo4TjdmMDZ3RERLeHNueUlocXJBeE4zVzh3Z3ZCSDNWRUVhM2ZMRzUtN2s2NnBtSlVERklJbzJValRSSGQxT2xMejdDZXhyaDZKRnVjbno1WF9Rd0owS2xpWkVnU1U?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals (SNDX) Is Up 5.2% After Strong All-Oral Revuforj SAVE Trial Data - What's Changed", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/syndax-pharmaceuticals-sndx-5-2-121208440.html", "source_name": "Simply Wall St.", "published_at": "2026-06-13T12:12:08+00:00", "published_display": "13 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax (SNDX) CMO sells 65,515 shares, retains 60,885 and large options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPazUwQUtkdGoxMjRmTS0wZEpqMW03WklLTk5ycXdiMVBOWGNUMTI5YmZtbWJobXNrRTJ1MnU3V01NSjByQlk5WjBJT1k0N2xCRjlvRmpHenBBQVlnVDUyVTlHa2dyN05MTjUzMHJuSFZ1bFRuVWdpVFBRWU5INlR0VjdGcl9KRlpCdm5SUGpGNGxXUWZGOFk2ai1RWFBrZWdhY1pqY2NSMTlmUDVRMk9TMzN5WXUxQVZQUFFJcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SNDX (NASDAQ) Rule 144 notice: Director-linked sale of 31,235 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPNm1hWTE5NjRsMDFhT2M1RDRaM2kwQXlrSFBYUzdlTlFNai05cnFMdXgzRU1ST1BNQ29Gd0l5dmNOdHVWcFZ3QWVkdVpVUjZhYzB3cy01b3owU3I3aE5NbE1IdERTeDVhd3JFeUdWZzREcUIyZnJ5TTFlRUlEQkFaSGgybFZXaU5mZmlfTE5vdWl4X3Rmd19Gbl9xM0R0ZXBsSlB4ZVV3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals Reports Positive Data From Leukemia Combo Drug Trial", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/syndax-pharmaceuticals-reports-positive-data-121728124.html", "source_name": "MT Newswires", "published_at": "2026-06-11T12:17:28+00:00", "published_display": "11 Jun 2026 12:17", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Showcases Revuforj\u00ae (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/syndax-showcases-revuforj-revumenib-clinical-110300065.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T11:03:00+00:00", "published_display": "11 Jun 2026 11:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Syndax Pharmaceuticals Inc SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPdk1NUXRxOTRDcExBXzJFNTY5RkRFOUVQb3YtWmIxRmI1UGMxcEFIZ0RtTzdXdXZEaEhCQnd2dFJKMHNOYzhCaUQ5bHNMZDNBLWFQaFp0c0lhVGh4WGt3ZXFYckZiMFdkUlhESDJiRXFkcE5vVGt0OG5ZY0g2ZHMzRlBtM053M1ZudkZiN2tnOUNVdFdVREYyTHdvX3QzUU9VUVQ3QUVn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax (NASDAQ: SNDX) raises $250M via 2.25% convertible notes due 2031", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOcFdGRXVnQmoyRkFsUEdHUG9DRlFxY1RqdFBnQVd4N05CUVQwZjk0cXJpWnVMdC1rOUxndEstMFNIczhuU1piQzFxRlRkbHp4cnRQY2lSSUdUdF9HS3NPekpHeFBKand2MEFZTnJlSjdxUjZkSjFSR0YxMEJ1TTZVZ1RzY25xTDhabF9oeHExV0NfRXRRdGRPU3dsRDlhdGFVSVhZeTJuZFJhd09YWVZDcmJaVEFRZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals Announces $250 Million Private Placement of Convertible Senior Notes | SNDX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPYTNuMFR4ODE3S213WXhKal9LS09jdzBlWmJMOC15VFgzY2VvU1FPRVFyNlQ4dGNKbEFCaDRhb1JBbXV5a2RCSUZqSUM5RlI0Y3cwMDhYNHdJM2hrUDJ5alhpV0RtUWdsOFBoT09sZlRvSUt5TkRvOFliTTJLVWZDdmhYQWZVUmJfS0ZuMUtITUxiRlZiMUtuUlp0Mm1halJ3czBxR00wdEhsN3RvSUlsd3BlWmJRdl92ZmYzUkd4RUYtYWVq?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax lines up $250M in 2.25% debt swappable into its stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOeEQ5ZjNiZVB4b1p2ajJLTE5HUW9yNXBEMjUxSXJjRmFFbkFRaVZnQjdfRGRtMnk3NW1sdnRxUE1MRWZ5UXkxRC0tdEhwUTVSNE1NUlBNS3JJRURhb2pYYUFpbGpLMjNoSGJBbHJpSW9INFYtV1g4Y003bXNSR3A3Xy04LXo3NTRwekRESE93clJYOTdQS3ljWFI0dWp0ekFFSy1fdVF3VFg3RlN0UlRzcThLanM5QXplQ2xMaGxn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Whether Syndax Pharmaceuticals (SNDX) Looks Undervalued After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNMEdKekJ5TkZEWHpmMEtQWGVDc2VacGhrWXJWOTVQZ1VOU2JjbDRsa1FEdUNTMHkyYkloX0xFRjhWSkNTMEVOcV9wb3VjbUJsdmZzMS1KVEhXQWJGNWVEbzZ5N1ZHZ1pQRVZJVUxRTnQ5ZldKM3JNanhIT1VjUUZUcXAwdnR5VVRxaDFnRm5kQTBjV3FZWlF4UVJKQzNRaWZSNlVhaU9nODAyVmFBY2E4?oc=5", "source_name": "Market source", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQMXdxMXl5QnFsMldCVGJBdjVtTEZBeEdQb0ZRaFlxRW9jMXppT00wbUxxYlowZmJqNXBhUkpuNUZTYU9YRVpiLVE1NU04UURmMmJWX1NKZjFQM245cm80bXN2WlFtb2xfNENGYUhhNTIwY3ZNM1Z6eERmN1VpWmZUaktnbUowcnlBR3dPa25ISE9JRHU1SXV6Z1BaTE5wRVcxNWc?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals (SNDX) Narrows Q1 Loss To US$42.7 Million Challenging Bearish Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer drug sales top $100M as Syndax lines up late-2026 trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNYkwtY0dLWldkVXJzcnNDUC1zdTlGX2hXdTJvRzE2RjVYSkZYTlpFNVBTZmxmMkpzZ0UxVXA4b1k1MUVVQzJmYXdENnExdG0wNDZyODYyMDN0OWdtYlhobjdnTy1zU2VUVzY3ekRGNGdLbDcyVEZCS3ppRUJKOFU5NmN2UTVfQ0FYY2Z0YWxhc2VoWXEyeV85M1VSTEs3Tjctako1Rk1KQnZPVG9lNDBvbFpHc1BsQlVIUWtv?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOaTd2VE93MmtDajBIaEtZT1BBSjVLOE9CUUJkYlY4bmVudlZzeksxNG9jT1dINE9iTnpxeTN3bnpXQjc4UjJ0b3dtaXFqTi1oYUJqb1NESWFkMFRqS04zdTY2UjQ0Y1VLTFZ5MG03OG1oQVNZeEhaUGRUbjUtR2djUWdlMFV6aVRhR04xWHF3WnQ4Q0o1SlpuN1NRMUZZbFFoUEJJWXktTFUzXzA?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Syndax\u2019s Third FDA Win Accelerates Shift To Multi Product Revenues", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Analysts See Syndax Pharmaceuticals (SNDX) Story Evolving With New Deals And Refined Valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxNVE9TTlFJQmp0dTdrM2RKX1hCVzc4NUZwLVhhMFVEVWRYMmdRam1iYzN3bzJaNTQyM0FXOWc0dW96YUVsMkRqeFlMejRGMXloRjRzZEk1NUYzYlVVY1FUYnFRTUo4Ry1rQ0JqVlZHcnZ1ZGhBY201dzU5akZQNWRSZnFaUkxQdUF3WVk4bmxR?oc=5", "source_name": "Market source", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Insiders Sold Syndax Pharmaceuticals Shares Recently?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Syndax Pharmaceuticals (NASDAQ:SNDX) Earns \"Buy\" Rating from HC Wainwright", "summary": "HC Wainwright has reiterated a \"buy\" rating on Syndax Pharmaceuticals (NASDAQ:SNDX), setting a $40 price target which suggests a 65.8% upside. The company reported better-than-expected quarterly EPS of ($0.48) and a significant year-over-year revenue increase of 224.3%, although ", "url": "https://www.marketbeat.com/instant-alerts/syndax-pharmaceuticals-nasdaqsndx-earns-buy-rating-from-hc-wainwright-2026-07-15/", "source_name": "MarketBeat", "published_at": "2026-07-15T12:46:50", "published_display": "15 Jul 2026 12:46", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Syndax Pharmaceuticals stock rating at buy", "summary": "H.C. Wainwright reiterated a Buy rating and a $40.00 price target for Syndax Pharmaceuticals (NASDAQ:SNDX) after the company's research and development day. The analyst firm highlighted two new assets, SNDX-62122 and SNDX-4321, with SNDX-62122 showing promise as a next-generation", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-syndax-pharmaceuticals-stock-rating-at-buy-93CH-4793279", "source_name": "Investing.com", "published_at": "2026-07-15T12:46:49", "published_display": "15 Jul 2026 12:46", "sentiment": "positive", "sentiment_pct": 81, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SNDX6417984 Bond Coupon Profile \u2014 Rate & Payments", "summary": "This article provides a bond coupon profile for Syndax Pharmaceuticals, Inc. (SNDX6417984). It indicates a current coupon rate of 2.25% with the next interest payment scheduled for December 15, 2026. The profile offers an overview of the bond's interest payments and redemption de", "url": "https://www.tradingview.com/symbols/FINRA-SNDX6417984/profile-coupon/", "source_name": "TradingView", "published_at": "2026-07-15T03:46:49", "published_display": "15 Jul 2026 03:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals Inc to Host R&D Day Transcript", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1tRXZvUFVnWG9QYVZzQzROcTYtWmJUWGFHd1piNkpiVVZ1SzE5ZC0xN0pvYzFCdzNmbVdsb2RYVWFaZ3Y2dkZSVFNSTzRqdDZnSE41R1hfeFVEdTRDRFluZHhlaGNsNmM?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-14T22:02:30+00:00", "published_display": "14 Jul 2026 22:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Fresh Look At Syndax Pharmaceuticals (NASDAQ:SNDX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxQdWdrWk1vMVc2QkNpTlctYU5iSkIwOG9qa0tmRmxiS29Cblp6cWl6UlduYTZvWUJGUzdyUjI0RGVjR0RNNnRKbV96cDFUd29yNFhfc21ZRnI5WTE1UzRSYWFfX1F3M2pSd3Z3cVpha0RueE11ODBPVzFLYWt5SlNkOG5lOGxfZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T20:48:00+00:00", "published_display": "14 Jul 2026 20:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SNDX6417984 Bond Profile \u2014 Key Metrics", "summary": "This article provides key metrics for the Syndax Pharmaceuticals, Inc. 2.25% 15-JUN-2031 bond, identified as SNDX6417984 FINRA. It details the bond's issuer, issue date, maturity date, outstanding amount, face value, minimum denomination, and coupon rate. Additionally, it gives a", "url": "https://www.tradingview.com/symbols/FINRA-SNDX6417984/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-14T21:14:05", "published_display": "14 Jul 2026 21:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push", "summary": "Syndax Pharmaceuticals is expanding its pipeline beyond its approved drugs Revuforj and Niktimvo, focusing on new indications in myelofibrosis and EGFR-mutated non-small cell lung cancer. The company plans a proof-of-principle trial for Revuforj in myelofibrosis and is advancing ", "url": "https://finance.yahoo.com/healthcare/articles/syndax-pharmaceuticals-maps-growth-beyond-200221267.html", "source_name": "Market source", "published_at": "2026-07-14T20:14:05", "published_display": "14 Jul 2026 20:14", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies - Slideshow (NASDAQ:SNDX)", "summary": "Syndax Pharmaceuticals, Inc. (SNDX) has published a slide deck discussing its pipeline expansion and the next phase of innovation for its lead therapies. This information was shared in conjunction with an event, indicating a focus on future development and strategic direction for", "url": "https://seekingalpha.com/article/4922013-syndax-pharmaceuticals-inc-sndx-discusses-pipeline-expansion-and-next-phase-of-innovation-for", "source_name": "Seeking Alpha", "published_at": "2026-07-14T16:40:27", "published_display": "14 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet", "summary": "Wall Street analysts project Syndax Pharmaceuticals (SNDX) could see a 70.38% surge, with a mean price target of $39. While price targets alone can be misleading, strong agreement among analysts on higher earnings estimates and a Zacks Rank #2 (Buy) suggest a potential upside. In", "url": "https://ca.finance.yahoo.com/news/wall-street-analysts-think-syndax-135502317.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-14T13:40:27", "published_display": "14 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SNDX: New pipeline assets and late-stage programs drive clinical and commercial growth through 2027", "summary": "Syndax Pharmaceuticals (SNDX) is expanding its pipeline with new EGFR and menin inhibitors and advancing late-stage programs in leukemia, GVHD, and IPF. The company anticipates multiple clinical milestones through 2027, supported by strategic partnerships and a strong financial s", "url": "https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3694655:0-sndx-new-pipeline-assets-and-late-stage-programs-drive-clinical-and-commercial-growth-through-2027/", "source_name": "TradingView", "published_at": "2026-07-14T12:40:27", "published_display": "14 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax (NASDAQ: SNDX) details pipeline expansion and 2026-27 clinical catalysts", "summary": "Syndax Pharmaceuticals (NASDAQ: SNDX) has outlined its expanded pipeline and clinical development plans for 2026-2027, including new assets SNDX-4321 for EGFR-mutated NSCLC and SNDX-62122 for myelofibrosis. The company also highlighted the commercial success of its FDA-approved d", "url": "https://www.stocktitan.net/sec-filings/SNDX/8-k-syndax-pharmaceuticals-inc-reports-material-event-dfbb39fcc295.html", "source_name": "Stock Titan", "published_at": "2026-07-14T12:40:27", "published_display": "14 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event", "summary": "Syndax Pharmaceuticals is hosting an R&D Event to showcase its late-stage programs and introduce new pipeline assets, SNDX-4321 for NSCLC and SNDX-62122 for MF. The company aims to expand its leadership in menin and CSF-1R inhibition, building on recent successes with Revuforj an", "url": "https://www.globenewswire.com/de/news-release/2026/07/14/3326768/0/en/Syndax-to-Highlight-Late-Stage-Programs-and-Unveil-New-Pipeline-Assets-at-R-D-Event.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T11:40:27", "published_display": "14 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Adds Two Pipeline Assets for Lung Cancer and Myelofibrosis", "summary": "Syndax Pharmaceuticals announced two new pipeline assets, SNDX-4321 for EGFR-mutated non-small cell lung cancer (NSCLC) and SNDX-62122 for myelofibrosis (MF), during its R&D event. SNDX-4321, a novel EGFR inhibitor, is expected to have an IND submission by year-end 2026 and a Pha", "url": "https://www.stocktitan.net/news/SNDX/syndax-to-highlight-late-stage-programs-and-unveil-new-pipeline-6e0syve6xmz8.html", "source_name": "Stock Titan", "published_at": "2026-07-14T11:40:27", "published_display": "14 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Reactions to SNDX Trends in Macro Strategies", "summary": "This article provides a technical analysis of Syndax Pharmaceuticals Inc. (NASDAQ: SNDX), highlighting strong sentiment across all time horizons and an exceptional 52.6:1 risk-reward setup. It outlines three institutional trading strategies (Position, Momentum Breakout, and Risk ", "url": "https://news.stocktradersdaily.com/news_release/20/Technical_Reactions_to_SNDX_Trends_in_Macro_Strategies_071026014202_1783662122.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-10T01:42:00", "published_display": "10 Jul 2026 01:42", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Syndax Pharmaceuticals For: 9 July By Investing.com", "summary": "This article from Investing.com announces a Form 4 filing for Syndax Pharmaceuticals, dated July 9th. The filing pertains to stock market activity for the company, whose stock symbol is SNDX. The brief entry reiterates the date and company information.", "url": "https://ng.investing.com/news/stock-market-news/form-4-syndax-pharmaceuticals-for-9-july-93CH-2593975", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T22:09:18", "published_display": "09 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells 32,375 Shares", "summary": "Syndax Pharmaceuticals CEO Michael Metzger sold 32,375 shares of SNDX stock on July 8th for approximately $784,770, reducing his stake by 6.26%. Despite the insider sale, the stock rose 1.1% to $24.84, nearing its 52-week high, and analysts maintain a \"Moderate Buy\" consensus wit", "url": "https://www.marketbeat.com/instant-alerts/syndax-pharmaceuticals-nasdaqsndx-ceo-sells-32375-shares-2026-07-09/", "source_name": "MarketBeat", "published_at": "2026-07-09T21:41:14", "published_display": "09 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax (SNDX) CEO Metzger exercises options and sells 32,375 shares under 10b5-1 plan", "summary": "Syndax Pharmaceuticals CEO Michael A. Metzger exercised stock options for 32,375 shares at $6.38 each and subsequently sold all 32,375 shares on the open market at an average price of $24.2402 per share. These transactions were executed under a pre-established Rule 10b5-1 trading", "url": "https://www.stocktitan.net/sec-filings/SNDX/form-4-syndax-pharmaceuticals-inc-insider-trading-activity-8881b521c490.html", "source_name": "Stock Titan", "published_at": "2026-07-09T21:41:14", "published_display": "09 Jul 2026 21:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals Insider Sold Shares Worth $784,776, According to a Recent SEC Filing", "summary": "An insider at Syndax Pharmaceuticals recently sold shares worth $784,776, as detailed in a recent SEC filing. The sale involved 31,500 shares at an average price of $24.91 per share. This transaction increases transparency regarding insider activity at the company.", "url": "https://www.moomoo.com/news/post/72735768/syndax-pharmaceuticals-insider-sold-shares-worth-784776-according-to-a?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-09T21:09:18", "published_display": "09 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Syndax Pharmaceuticals For: 8 July By Investing.com", "summary": "This article from Investing.com reports on a Form 144 filing for Syndax Pharmaceuticals (SNDX) for July 8, 2026. The brief piece indicates that shares of Syndax Pharmaceuticals were up 5.68% at the time of publication, suggesting market interest stemming from the filing.", "url": "https://ca.investing.com/news/stock-market-news/form-144-syndax-pharmaceuticals-for-8-july-93CH-4726031", "source_name": "Investing.com Canada", "published_at": "2026-07-08T21:10:17", "published_display": "08 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SNDX insider files to sell 32,375 shares (NASDAQ: SNDX)", "summary": "A Form 144 filing indicates a proposed sale of 32,375 shares of Syndax Pharmaceuticals Inc (NASDAQ: SNDX) common stock on July 8, 2026, through the exercise of stock options. The filing also disclosed a previous sale of 6,847 shares on June 1, 2026, for $130,024.53. The transacti", "url": "https://www.stocktitan.net/sec-filings/SNDX/144-syndax-pharmaceuticals-inc-sec-filing-6ba5df804cdd.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:10:17", "published_display": "08 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Syndax Pharmaceuticals (SNDX) Is Up 6.3% After Broad Russell Value Index Removal And What's Next", "summary": "Syndax Pharmaceuticals (SNDX) experienced a 6.3% increase in stock value despite being removed from several Russell value indexes on June 27, 2026. This removal primarily impacts the stock's ownership structure and trading patterns due to benchmark-driven portfolio rebalancing, r", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/why-syndax-pharmaceuticals-sndx-is-up-63-after-broad-russell", "source_name": "Simply Wall Street", "published_at": "2026-07-08T09:10:48", "published_display": "08 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals holds steady as investors await a fresh catalyst", "summary": "Syndax Pharmaceuticals (SNDX) stock is holding steady with no immediate new market-moving filings, shifting focus to its US-listed setup and pipeline. The company, a US biotech firm specializing in oncology and hematology, relies heavily on clinical data, regulatory milestones, a", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/syndax-pharmaceuticals-holds-steady-as-investors-await-a-fresh-catalyst/69714064", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T12:40:11", "published_display": "07 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SG Americas Securities LLC Has $900,000 Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX", "summary": "SG Americas Securities LLC reduced its stake in Syndax Pharmaceuticals by 70.2% in Q1, now holding 38,548 shares worth $900,000. Despite this, the company has an average \"Moderate Buy\" rating, although some analysts like Weiss Ratings maintain a \"sell.\" Recent insider selling by ", "url": "https://www.marketbeat.com/instant-alerts/filing-sg-americas-securities-llc-has-900000-stock-holdings-in-syndax-pharmaceuticals-inc-sndx-2026-07-06/", "source_name": "MarketBeat", "published_at": "2026-07-06T09:11:07", "published_display": "06 Jul 2026 09:11", "sentiment": "negative", "sentiment_pct": 37, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals (SNDX) Reports Strong Revuforj Data, Is The Upside Already Priced In?", "summary": "Syndax Pharmaceuticals (SNDX) recently released encouraging Phase 1/2 data for its Revuforj combination regimen in acute myeloid leukemia, showing high response rates and attracting investor interest. Despite a significant one-year share price return, the stock is trading below a", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-sndx-reports-strong-revuforj-data-is", "source_name": "Simply Wall Street", "published_at": "2026-07-04T20:40:46", "published_display": "04 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)", "summary": "Syndax Pharmaceuticals announced inducement grants to eight new employees for up to 250,700 shares of common stock under its 2023 Inducement Plan. These stock options will vest over four years, with a portion vesting on the one-year anniversary and the remainder monthly thereafte", "url": "https://www.globenewswire.com/news-release/2026/07/01/3320972/0/en/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-07-02T07:09:46", "published_display": "02 Jul 2026 07:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax awards stock options to 8 new hires in July", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQeXVtM2lqcXNmZC10aXdDLU5SQ3M3WFZQa3VXZDZld18yZmlYc0VJVzVVR0tEQ0dmd1hFQVgtT1JrUW1mM2E5Yi1LZ3R0NTNqUXZDS25OUEhyMTl4UjVQNDRzQzRqWXRGLVFaYzNrblNjSHkzM2h6MVc0elVhY3RKSjFBci1ZM0d6QTNSWFd4b2xMMm8wYS1XQ1NyVm9UaGdKalRrYlR2WDZGUTY4TFcwT1RRZzNhS0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of \"Moderate Buy\" by Analysts", "summary": "Syndax Pharmaceuticals (NASDAQ:SNDX) has received a \"Moderate Buy\" consensus rating from analysts, with an average 12-month price target of $42.55. Recent analyst updates include price target increases from JPMorgan, Barclays, and Goldman Sachs, though Wall Street Zen downgraded ", "url": "https://www.marketbeat.com/instant-alerts/syndax-pharmaceuticals-inc-nasdaqsndx-given-consensus-rating-of-moderate-buy-by-analysts-2026-07-01/", "source_name": "MarketBeat", "published_at": "2026-07-01T06:09:30", "published_display": "01 Jul 2026 06:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Purchase/sale of business (net) of Syndax Pharmaceuticals Inc \u2013 SWB:1T3", "summary": "This article provides financial information for Syndax Pharmaceuticals Inc, listed on the Stuttgart Stock Exchange under the ticker SWB:1T3. It specifically highlights the \"Purchase/sale of business (net)\" data, indicating that currently, there are no recorded values for this met", "url": "https://www.tradingview.com/symbols/SWB-1T3/financials-cash-flow/purchase-sale-business/", "source_name": "TradingView", "published_at": "2026-06-30T08:40:20", "published_display": "30 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPNWtMam05Z1JYQ0ptZzZOUXVtVlVOQXFOSnZKZ19mQ212VVlqX213UndyVnU0OVhQeVpRRGNsWHlDMGo4TjdmMDZ3RERLeHNueUlocXJBeE4zVzh3Z3ZCSDNWRUVhM2ZMRzUtN2s2NnBtSlVERklJbzJValRSSGQxT2xMejdDZXhyaDZKRnVjbno1WF9Rd0owS2xpWkVnU1U?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals (SNDX) Is Up 5.2% After Strong All-Oral Revuforj SAVE Trial Data - What's Changed", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/syndax-pharmaceuticals-sndx-5-2-121208440.html", "source_name": "Simply Wall St.", "published_at": "2026-06-13T12:12:08+00:00", "published_display": "13 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax (SNDX) CMO sells 65,515 shares, retains 60,885 and large options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPazUwQUtkdGoxMjRmTS0wZEpqMW03WklLTk5ycXdiMVBOWGNUMTI5YmZtbWJobXNrRTJ1MnU3V01NSjByQlk5WjBJT1k0N2xCRjlvRmpHenBBQVlnVDUyVTlHa2dyN05MTjUzMHJuSFZ1bFRuVWdpVFBRWU5INlR0VjdGcl9KRlpCdm5SUGpGNGxXUWZGOFk2ai1RWFBrZWdhY1pqY2NSMTlmUDVRMk9TMzN5WXUxQVZQUFFJcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SNDX (NASDAQ) Rule 144 notice: Director-linked sale of 31,235 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPNm1hWTE5NjRsMDFhT2M1RDRaM2kwQXlrSFBYUzdlTlFNai05cnFMdXgzRU1ST1BNQ29Gd0l5dmNOdHVWcFZ3QWVkdVpVUjZhYzB3cy01b3owU3I3aE5NbE1IdERTeDVhd3JFeUdWZzREcUIyZnJ5TTFlRUlEQkFaSGgybFZXaU5mZmlfTE5vdWl4X3Rmd19Gbl9xM0R0ZXBsSlB4ZVV3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals Reports Positive Data From Leukemia Combo Drug Trial", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/syndax-pharmaceuticals-reports-positive-data-121728124.html", "source_name": "MT Newswires", "published_at": "2026-06-11T12:17:28+00:00", "published_display": "11 Jun 2026 12:17", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Showcases Revuforj\u00ae (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/syndax-showcases-revuforj-revumenib-clinical-110300065.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T11:03:00+00:00", "published_display": "11 Jun 2026 11:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Syndax Pharmaceuticals Inc SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPdk1NUXRxOTRDcExBXzJFNTY5RkRFOUVQb3YtWmIxRmI1UGMxcEFIZ0RtTzdXdXZEaEhCQnd2dFJKMHNOYzhCaUQ5bHNMZDNBLWFQaFp0c0lhVGh4WGt3ZXFYckZiMFdkUlhESDJiRXFkcE5vVGt0OG5ZY0g2ZHMzRlBtM053M1ZudkZiN2tnOUNVdFdVREYyTHdvX3QzUU9VUVQ3QUVn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax (NASDAQ: SNDX) raises $250M via 2.25% convertible notes due 2031", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOcFdGRXVnQmoyRkFsUEdHUG9DRlFxY1RqdFBnQVd4N05CUVQwZjk0cXJpWnVMdC1rOUxndEstMFNIczhuU1piQzFxRlRkbHp4cnRQY2lSSUdUdF9HS3NPekpHeFBKand2MEFZTnJlSjdxUjZkSjFSR0YxMEJ1TTZVZ1RzY25xTDhabF9oeHExV0NfRXRRdGRPU3dsRDlhdGFVSVhZeTJuZFJhd09YWVZDcmJaVEFRZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals Announces $250 Million Private Placement of Convertible Senior Notes | SNDX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPYTNuMFR4ODE3S213WXhKal9LS09jdzBlWmJMOC15VFgzY2VvU1FPRVFyNlQ4dGNKbEFCaDRhb1JBbXV5a2RCSUZqSUM5RlI0Y3cwMDhYNHdJM2hrUDJ5alhpV0RtUWdsOFBoT09sZlRvSUt5TkRvOFliTTJLVWZDdmhYQWZVUmJfS0ZuMUtITUxiRlZiMUtuUlp0Mm1halJ3czBxR00wdEhsN3RvSUlsd3BlWmJRdl92ZmYzUkd4RUYtYWVq?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax lines up $250M in 2.25% debt swappable into its stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOeEQ5ZjNiZVB4b1p2ajJLTE5HUW9yNXBEMjUxSXJjRmFFbkFRaVZnQjdfRGRtMnk3NW1sdnRxUE1MRWZ5UXkxRC0tdEhwUTVSNE1NUlBNS3JJRURhb2pYYUFpbGpLMjNoSGJBbHJpSW9INFYtV1g4Y003bXNSR3A3Xy04LXo3NTRwekRESE93clJYOTdQS3ljWFI0dWp0ekFFSy1fdVF3VFg3RlN0UlRzcThLanM5QXplQ2xMaGxn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Whether Syndax Pharmaceuticals (SNDX) Looks Undervalued After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNMEdKekJ5TkZEWHpmMEtQWGVDc2VacGhrWXJWOTVQZ1VOU2JjbDRsa1FEdUNTMHkyYkloX0xFRjhWSkNTMEVOcV9wb3VjbUJsdmZzMS1KVEhXQWJGNWVEbzZ5N1ZHZ1pQRVZJVUxRTnQ5ZldKM3JNanhIT1VjUUZUcXAwdnR5VVRxaDFnRm5kQTBjV3FZWlF4UVJKQzNRaWZSNlVhaU9nODAyVmFBY2E4?oc=5", "source_name": "Market source", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQMXdxMXl5QnFsMldCVGJBdjVtTEZBeEdQb0ZRaFlxRW9jMXppT00wbUxxYlowZmJqNXBhUkpuNUZTYU9YRVpiLVE1NU04UURmMmJWX1NKZjFQM245cm80bXN2WlFtb2xfNENGYUhhNTIwY3ZNM1Z6eERmN1VpWmZUaktnbUowcnlBR3dPa25ISE9JRHU1SXV6Z1BaTE5wRVcxNWc?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals (SNDX) Narrows Q1 Loss To US$42.7 Million Challenging Bearish Narratives", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxOc1JKUXo3SGZVM1Z4U1NFdFYwN01uVkY2WGZRTWxkSTlMZndRU003enp6cEpKY2x4QTI1RlhqNkdZQU9IRHRiUHdObXRJa2t3NFUzOEtFM2h3RUJmMW15QkxMamx2c2Vna3R6cU5ObWo2V3k3VHpwNFRhZDBaWG80cXlkSnRGY1RIcWxkeW4zYnJzZXpObUo0YzllaXkzd2w4cnBFVGVPcTJWS3h0T28tVE9MSVZLMy1CVDZUUWpJVVNRZmZsN2gtRnVOTTZsUkZZS1U4dUFXazFVZzVYblowckpmeG1BSkhBek5GRtIB8gFBVV95cUxNN0JWLWRYSkxXdXlYRDVmZExoNU5tRTRITXdINFRja0Rfd0NINlh6bVNFRWdPUURpS2tyR19tYVFqTmJ2WGJwTEZ5QTIwU2tINHQ5Q0tUaEZqMG1rLW94ZWFTbzc1WXhjZHFqS2NCd1Fxd1dBdkNBQ3VYMlByc3dNMVRiSVNKTkx6enpEUjFlbTNGUzl0WDJBVFZlcGd6ZGFrdGFHajd2MVFBeWVpUTYyNFVkZ1FVbHJ3Vk01Rk1LQW9CRjFlWlJweENjNTc0R0hDYVhMdnFmd1NqOFhseXpjMmhHcDdPNEY4V1o5U0VnNWVudw?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer drug sales top $100M as Syndax lines up late-2026 trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNYkwtY0dLWldkVXJzcnNDUC1zdTlGX2hXdTJvRzE2RjVYSkZYTlpFNVBTZmxmMkpzZ0UxVXA4b1k1MUVVQzJmYXdENnExdG0wNDZyODYyMDN0OWdtYlhobjdnTy1zU2VUVzY3ekRGNGdLbDcyVEZCS3ppRUJKOFU5NmN2UTVfQ0FYY2Z0YWxhc2VoWXEyeV85M1VSTEs3Tjctako1Rk1KQnZPVG9lNDBvbFpHc1BsQlVIUWtv?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOaTd2VE93MmtDajBIaEtZT1BBSjVLOE9CUUJkYlY4bmVudlZzeksxNG9jT1dINE9iTnpxeTN3bnpXQjc4UjJ0b3dtaXFqTi1oYUJqb1NESWFkMFRqS04zdTY2UjQ0Y1VLTFZ5MG03OG1oQVNZeEhaUGRUbjUtR2djUWdlMFV6aVRhR04xWHF3WnQ4Q0o1SlpuN1NRMUZZbFFoUEJJWXktTFUzXzA?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Syndax\u2019s Third FDA Win Accelerates Shift To Multi Product Revenues", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Analysts See Syndax Pharmaceuticals (SNDX) Story Evolving With New Deals And Refined Valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxNVE9TTlFJQmp0dTdrM2RKX1hCVzc4NUZwLVhhMFVEVWRYMmdRam1iYzN3bzJaNTQyM0FXOWc0dW96YUVsMkRqeFlMejRGMXloRjRzZEk1NUYzYlVVY1FUYnFRTUo4Ry1rQ0JqVlZHcnZ1ZGhBY201dzU5akZQNWRSZnFaUkxQdUF3WVk4bmxR?oc=5", "source_name": "Market source", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Insiders Sold Syndax Pharmaceuticals Shares Recently?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 55, "sentiment_summary": {"positive": 18, "negative": 6, "neutral": 31, "score": 56, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 19.95, "count": 35}, {"event": "earnings", "label": "Earnings", "weight": 5.5, "count": 12}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 18, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 23.61, "latest_week": "2026-07-10", "one_week_move": 8.2, "four_week_move": 29.4, "twelve_week_move": -2.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.400547, "market_dynamics_buy_signal": false, "relative_strength": 8.425928, "fair_value_gap": 32.5, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 52.8432, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+8.2% over one week, +29.4% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "Stock Titan", "count": 11}, {"label": "simplywall.st", "count": 6}, {"label": "TradingView", "count": 5}, {"label": "MarketBeat", "count": 4}, {"label": "GlobeNewswire", "count": 3}, {"label": "Seeking Alpha", "count": 2}, {"label": "Simply Wall Street", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 47}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 35}, {"label": "Earnings", "count": 12}, {"label": "Analyst action", "count": 3}, {"label": "Regulatory and legal", "count": 2}, {"label": "Deals and strategy", "count": 1}, {"label": "Macro sensitivity", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "47", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+8.2% over one week, +29.4% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Syndax Pharmaceuticals (NASDAQ:SNDX) Earns \"Buy\" Rating from HC Wainwright"}], "updated_at": "2026-07-16T11:43:14.519072+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}